Enhancement of NK cell antitumor responses using an oncolytic parvovirus

International Journal of Cancer

Volumn 128, Issue 4, 2011, Pages 908-919

  Bhat, Rauf ^a   Dempe, Sebastian ^a   Dinsart, Christiane ^a   Rommelaere, Jean ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

cytotoxicity; human natural killer cells; IL 2; pancreatic ductal adenocarcinoma; parvovirus

Indexed keywords

CD155 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 15; INTERLEUKIN 2; LYMPHOCYTE ANTIGEN; LYMPHOCYTE RECEPTOR; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL CYTOTOXICITY RECEPTOR P30; NATURAL CYTOTOXICITY RECEPTOR P44; NATURAL CYTOTOXICITY RECEPTOR P46; NATURAL KILLER CELL RECEPTOR NKG2D; ONCOLYTIC PARVOVIRUS; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXICITY; DOWN REGULATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOSTIMULATION; INNATE IMMUNITY; NATURAL KILLER CELL; PANCREAS CARCINOMA; PRIORITY JOURNAL; UPREGULATION;

CARCINOMA, PANCREATIC DUCTAL; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; H-1 PARVOVIRUS; HUMANS; KILLER CELLS, NATURAL; ONCOLYTIC VIRUSES; PANCREATIC NEOPLASMS; PARVOVIRIDAE INFECTIONS; TUMOR CELLS, CULTURED;

EID: 78650609261     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25415     Document Type: Article

References (35)

1. Trinchieri G,. Biology of natural killer cells. Adv Immunol 1989; 47: 187-376.
2. Kleeff J, Beckhove P, Esposito I, Herzig S, Huber PE, Lohr JM, Friess H,. Pancreatic cancer microenvironment. Int J Cancer 2007; 121: 699-705.
3. von Bernstorff W, Voss M, Freichel S, Schmid A, Vogel I, Johnk C, Henne-Bruns D, Kremer B, Kalthoff H,. Systemic and local immunosuppression in pancreatic cancer patients. Clin Cancer Res 2001; 7: 925s-32s.
4. Waldmann TA,. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 2006; 6: 595-601.
5. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP,. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 1999; 17: 189-220.
6. Lanier LL,. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 2008; 9: 495-502.
7. Moretta L, Bottino C, Pende D, Castriconi R, Mingari MC, Moretta A,. Surface NK receptors and their ligands on tumor cells. Semin Immunol 2006; 18: 151-8.
8. Biassoni R,. Human natural killer receptors, co-receptors, and their ligands (Review). Curr Protoc Immunol 2010; 126: 291-27.
9. Rommelaere J, Cornelis JJ,. Antineoplastic activity of parvoviruses. J Virol Methods 1991; 33: 233-51.
10. Cotmore SF, Tattersall P,. The autonomously replicating parvoviruses of vertebrates. Adv Virus Res 1987; 33: 91-174.
11. Haag A, Menten P, van Damme J, Dinsart C, Rommelaere J, Cornelis JJ,. Highly efficient transduction and expression of cytokine genes in human tumor cells by means of autonomous parvovirus vectors; generation of antitumor responses in recipient mice. Hum Gene Ther 2000; 11: 597-609.
12. Faisst S, Schlehofer JR, zur Hausen H,. Transformation of human cells by oncogenic viruses supports permissiveness for parvovirus H-1 propagation. J Virol 1989; 63: 2152-8.
13. Angelova AL, Aprahamian M, Grekova SP, Hajri A, Leuchs B, Giese NA, Dinsart C, Herrmann A, Balboni G, Rommelaere J, Raykov Z,. Improvement of gemcitabine-based therapy of pancreatic carcinoma by means of oncolytic parvovirus H-1PV. Clin Cancer Res 2009; 15: 511-9.
14. Errington F, Steele L, Prestwich R, Harrington KJ, Pandha HS, Vidal L, de Bono J, Selby P, Coffey M, Vile R, Melcher A,. Reovirus activates human dendritic cells to promote innate antitumor immunity. J Immunol 2008; 180: 6018-26.
15. Dempe S, Stroh-Dege A, Schwarz E, Rommelaere J, Dinsart C,. 2009. SMAD4: a predictive marker of PDAC cell permissiveness for oncolytic infection with parvovirus, H-1PV. Int J Cancer 2009; Chapter 14: Unit 14.10.
16. Mainiero F, Soriani A, Strippoli R, Jacobelli J, Gismondi A, Piccoli M, Frati L, Santoni A,. RAC1/P38 MAPK signaling pathway controls beta1 integrin-induced interleukin-8 production in human natural killer cells. Immunity 2000; 12: 7-16.
17. Cornelis JJ, Spruyt N, Spegelaere P, Guetta E, Darawshi T, Cotmore SF, Tal J, Rommelaere J,. Sensitization of transformed rat fibroblasts to killing by parvovirus minute virus of mice correlates with an increase in viral gene expression. J Virol 1988; 62: 3438-44.
18. Wrzesinski C, Tesfay L, Salome N, Jauniaux JC, Rommelaere J, Cornelis J, Dinsart C,. Chimeric and pseudotyped parvoviruses minimize the contamination of recombinant stocks with replication-competent viruses and identify a DNA sequence that restricts parvovirus H-1 in mouse cells. J Virol 2003; 77: 3851-8.
19. Zolotukhin S, Byrne BJ, Mason E, Zolotukhin I, Potter M, Chesnut K, Summerford C, Samulski RJ, Muzyczka N,. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther 1999; 6: 973-85.
20. Kestler J, Neeb B, Struyf S, van Damme J, Cotmore SF, D'Abramo A, Tattersall P, Rommelaere J, Dinsart C, Cornelis JJ,. Cis requirements for the efficient production of recombinant DNA vectors based on autonomous parvoviruses. Hum Gene Ther 1999; 10: 1619-32.
21. Cook DN,. The role of MIP-1 alpha in inflammation and hematopoiesis. J Leukoc Biol 1996; 59: 61-6.
22. Jonjic S, Babic M, Polic B, Krmpotic A,. Immune evasion of natural killer cells by viruses. Curr Opin Immunol 2008; 20: 30-8.
23. Jarahian M, Watzl C, Fournier P, Arnold A, Djandji D, Zahedi S, Cerwenka A, Paschen A, Schirrmacher V, Momburg F,. Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase. J Virol 2009; 83: 8108-21.
24. Biron CA,. Activation and function of natural killer cell responses during viral infections. Curr Opin Immunol 1997; 9: 24-34.
25. Bryceson YT, Ljunggren HG, Long EO,. Minimal requirement for induction of natural cytotoxicity and intersection of activation signals by inhibitory receptors. Blood 2009; 114: 2657-66.
26. Soriani A, Zingoni A, Cerboni C, Iannitto ML, Ricciardi MR, Di Gialleonardo V, Cippitelli M, Fionda C, Petrucci MT, Guarini A, Foa R, Santoni A,. ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood 2009; 113: 3503-11.
27. Cerwenka A,. New twist on the regulation of NKG2D ligand expression. J Exp Med 2009; 206: 265-8.
28. Gilfillan S, Chan CJ, Cella M, Haynes NM, Rapaport AS, Boles KS, Andrews DM, Smyth MJ, Colonna M,. DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J Exp Med 2008; 205: 2965-73.
29. Mandelboim O, Malik P, Davis DM, Jo CH, Boyson JE, Strominger JL,. Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity. Proc Natl Acad Sci USA 1999; 96: 5640-4.
30. Salih HR, Rammensee HG, Steinle A,. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol 2002; 169: 4098-4102.
31. Schmitz-Winnenthal FH, Escobedo LV, Beckhove P, Schirrmacher V, Bucur M, Ziouta Y, Volk C, Schmied B, Koch M, Antolovic D, Weitz J, Buchler MW, et al. Specific immune recognition of pancreatic carcinoma by patient-derived CD4 and CD8 T cells and its improvement by interferon-gamma. Int J Oncol 2006; 28: 1419-28.
32. Russell SJ, Brandenburger A, Flemming CL, Collins MK, Rommelaere J,. Transformation-dependent expression of interleukin genes delivered by a recombinant parvovirus. J Virol 1992; 66: 2821-8.
33. Wetzel K, Struyf S, van Damme J, Kayser T, Vecchi A, Sozzani S, Rommelaere J, Cornelis JJ, Dinsart C,. MCP-3 (CCL7) delivered by parvovirus MVMp reduces tumorigenicity of mouse melanoma cells through activation of T lymphocytes and NK cells. Int J Cancer 2007; 120: 1364-71.
34. Janke M, Peeters B, Zhao H, de Leeuw O, Moorman R, Arnold A, Ziouta Y, Fournier P, Schirrmacher V,. Activation of human T cells by a tumor vaccine infected with recombinant Newcastle disease virus producing IL-2. Int J Oncol 2008; 33: 823-32.
35. Prestwich RJ, Errington F, Steele LP, Ilett EJ, Morgan RS, Harrington KJ, Pandha HS, Selby PJ, Vile RG, Melcher AA,. Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus. J Immunol 2009; 183: 4312-21.